Preterm pre-eclampsia: What every neonatologist should know

Research output: Contribution to journalReview articlepeer-review

20 Citations (Scopus)


Although pre-eclampsia affects 5–10% of pregnancies globally and is responsible for substantial maternal and perinatal morbidity and mortality, currently there is no cure other than delivery of the baby. Predictive screening tests based on clinical risk factors, with or without the addition of biomarkers and imaging, have been developed, but adoption into clinical practice is limited by suboptimal test performance. Once established pre-eclampsia is diagnosed, a woman is usually managed expectantly prior to 37 weeks' gestation to reduce perinatal morbidity and mortality associated with iatrogenic prematurity until maternal or fetal triggers for delivery mean that risks of pregnancy prolongation outweigh the benefits. Associated fetal growth restriction is a common feature of pre-eclampsia, particularly with early-onset disease, and will influence decisions for delivery and subsequent neonatal course. Prematurity and fetal growth restriction both have potential short and long-term consequences for the infant and child.
Original languageEnglish
JournalEarly Human Development
Publication statusE-pub ahead of print - 13 Sept 2017


  • Pre-eclampsia
  • Hypertension
  • Pregnancy
  • Fetal growth restriction


Dive into the research topics of 'Preterm pre-eclampsia: What every neonatologist should know'. Together they form a unique fingerprint.

Cite this